CASR and neuroblastoma: Studies on human patient samples with relatively superior prognostic variables like low clinical stage and clinical risk and age of diagnosis below one year had confirmed CaSR expression on nearly 50% of both fully and partially differentiating neuroblastoma, along with the expression of PTHrP.